Haemonetics Corporation’s HAE share price has dipped by 11.58%, which has investors questioning if this is right time to buy.

Learn more about whether Haemonetics Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

While reporting financial results for the third quarter on Thursday, healthcare company Haemonetics Corp. (HAE) narrowed its adjusted ...

BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...

Based on the one-year price targets offered by 10 analysts, the average target price for Haemonetics Corp (NYSE:HAE) is $110.80 with a high estimate of $125.00 and a low estimate of $85.00.

Net Leverage Ratio: Approximately 2.42 times EBITDA. Haemonetics Corp (NYSE:HAE) reported a 4% increase in third-quarter revenue on a reported basis, with adjusted earnings per share up 14%.

Q3 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, and welcome to the Haemonetics Third Quarter Fiscal ...

Haemonetics Corporation (NYSE:HAE) stock dropped about 12% after the blood supplies company missed Q3 revenue estimates, despite posting a 3.7% year-over-year increase. Quarterly revenue came in ...

Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ETCompany ParticipantsOlga Guyette - Vice President, ...

Analysts expect Haemonetics to post earnings of $1.20 per share and revenue of $354.46 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so ...